Abstract 201P
Background
Approved ADCs have been developed for a diverse array of targets. However, a predictive biomarker for ADCs remains elusive, except for HER2. Herein, we evaluated the efficacy of ADC by mRNA expression level of targeted genes in advanced solid tumors from the SCRUM-Japan MONSTAR-SCREEN-2, a nationwide molecular profiling project (UMIN000043899).
Methods
Patients (pts) with advanced solid tumors were enrolled; whole exome/transcriptome sequencing by Caris Life Sciences (Phoenix, AZ, USA) and immunohistochemistry (IHC) of HER2 were performed.
Results
Among 2,037 pts enrolled as of July 2023, mRNA expression data of baseline tissue samples were available in 1,418 pts across 30 cancer subtypes: most common subtypes were colorectal (n=332), gastric (n=181), pancreatic (n=113) and breast cancers (n=107). ERBB2 mRNA and HER2 IHC expression were highly concordant (AUC, 0.92). Since HER2 overexpression in IHC corresponded to the top 9.3 percentile of mRNA level across all solid tumors, we defined the cutoff for high mRNA expression as the top 9.3 percentile. Seventy-one percent of the high mRNA expression of target genes for FDA-approved ADCs, such as HER2, Nectin-4, TROP-2, Tissue factor and Folate receptor, was found in off-label cancer types. In 52 patients treated with ADC monotherapy, the high mRNA expression group tended to have a better objective response rate (ORR) and significantly better progression-free survival (PFS) than the non-high mRNA expression group (ORR: 51.7% vs 30.4%, P = 0.16, PFS: 6.9 vs 3.0 months, hazard ratio [HR]: 0.40, 95% CI: 0.20-0.81). The significant difference in PFS was independent of ADC targets and cancer types.
Conclusions
High mRNA levels were associated with better therapeutic efficacy of ADCs, highlighting the potential of mRNA level as a predictive biomarker of ADCs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center Hospital East.
Funding
Scrum-Japan.
Disclosure
T. Fujisawa: Financial Interests, Personal, Invited Speaker: Amelieff Co Ltd.. Y. Nakamura: Financial Interests, Personal, Invited Speaker: Chugai, Merck Biopharma, Guardant Health Pte Ltd, MSD K.K, Eisai, Zeria Pharmaceutical, Miyarisan pharmaceutical, CareNet, Inc., Hisamitsu Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo Co., Ltd., Becton Dickinson, Guardant Health Japan Corp.; Financial Interests, Personal, Advisory Board: Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda, Exact Sciences, Gilead Sciences, Guardant Health Pte Ltd; Financial Interests, Institutional, Funding: Taiho, Chugai, Guardant Health, Genomedia, Daiichi Sankyo, Roche Diagnostics, Guardant Health AMEA, Inc., Tempus; Financial Interests, Institutional, Coordinating PI: Seagen. M. Nagamine: Financial Interests, Personal, Advisory Role: GxD, Inc.; Financial Interests, Personal, Advisory Board: SRL, Inc.; Financial Interests, Personal, Speaker’s Bureau: Chugai Pharmaceutical Co., Ltd.. T. Kuwata: Financial Interests, Personal, Writing Engagement: Astellas; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, FALCO Biosystems, MSD, Roche Diagnostics; Financial Interests, Institutional, Research Grant: Takeda. G. Ishii: Financial Interests, Institutional, Research Grant: Daiichi Sankyo, INC., Ono Pharmaceutical Co., Ltd., Noile-Immune Biotech, Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Ltd., Nihon Medi-Physics Co., Ltd., Indivumed GmbH, H.U. Group Research Institute; Financial Interests, Personal, Advisory Role: Takeda Pharmaceutical Company Limited; Financial Interests, Personal, Speaker’s Bureau: Roche Diagnostics K.K., Chugai Pharmaceutical Co., Ltd., Novartis International AG, Eli Lilly Japan K.K., Takeda Pharmaceutical Company Limited, AstraZeneca, Riken Genesis Co., Ltd., Merck Biopharma Japan. C. Morizane: Financial Interests, Personal, Advisory Board: Yakult, MSD, Servier, Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceutical, Merck biopharma; Financial Interests, Personal, Invited Speaker: Novartis, Teijin Pharma; Financial Interests, Institutional, Coordinating PI: Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, Eisai, MSD K.K., J-Pharma, AstraZeneca, Merck biopharma; Financial Interests, Institutional, Funding: Daiichi Sankyo RD Novare, Hitachi. H. Iwata: Financial Interests, Personal, Advisory Board: Chugai, Daiichi Sankyo, AstraZeneca, Lilly, Sanofi; Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo, AstraZeneca, Lilly, Pfizer, Sanofi, Taiho; Financial Interests, Personal and Institutional, Steering Committee Member: Chugai, Daiichi Sankyo, AstraZeneca, MSD, Amgen, Sanofi, Novartis, Pfizer, Kyowa Hakko Kirin; Financial Interests, Personal and Institutional, Local PI: Lilly, Bayer, Behringer, Nihon Kayaku. S. Okano: Financial Interests, Personal, Invited Speaker: MSD, Merck Biophama Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb. K. Namikawa: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Novartis Pharma, MSD, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Novartis Pharma, MSD. M. Imai-Sumida: Financial Interests, Personal, Advisory Role: Sumitomo Corporation Ltd.; Financial Interests, Personal, Advisory Board: Exact Science Inc., Caris Life Sciences; Financial Interests, Personal, Speaker’s Bureau: Chugai Pharmaceutical Co.. H. Bando: Financial Interests, Institutional, Research Grant: Ono pharmaceutical; Other, Lecture fee: Ono pharmaceutical, Taiho pharmaceutical, Eli Lilly Japan. M. Radovich, G. Sledge: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. T. Yoshino: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd.; Financial Interests, Personal, Other, Consultancy: Sumitomo Corp.; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical Co., Ltd, Sanofi K.K., MSD K.K., Taiho Pharmaceutical Co., Ltd., Molecular Health GmbH, Amgen K.K., Pfizer Japan Inc., Genomedia Inc., Sysmex Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Roche Diagnostics K.K., FALCO Biosystems Ltd., Merus N.V., Bristol Myers Squibb K.K., Medical & Biological Laboratories Co., LTD., Takeda Pharmaceutical Co., Ltd.. All other authors have declared no conflicts of interest.
Resources from the same session
142P - Exploring tumor mutational burden and frameshift mutations as predictors of immune checkpoint inhibitor efficacy
Presenter: Mai Hoshino
Session: Poster session 08
143P - Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype
Presenter: Emily Alouani
Session: Poster session 08
144P - Analysis of a novel predictive marker of immune checkpoint response in head and neck cancer, calculated from histopathological slides through inferred transcriptomics
Presenter: Johnathan Arnon
Session: Poster session 08
145P - Predicting the efficacy of immunotherapy in non-small cell lung cancer using machine learning based on simple clinical characteristics and biochemical indexes
Presenter: Lei Cheng
Session: Poster session 08
146P - Biomarkers and intrinsic/acquired resistance mechanisms for atezolizumab plus chemoradiotherapy in MSS locally advanced rectal cancer: An exploratory analysis of a single center, phase II study
Presenter: Wentao Tang
Session: Poster session 08
147P - Comparison of immune-checkpoint inhibitor therapy predictive marker tests microsatellite instability (MSI) and mismatch-repair deficiency (dMMR)
Presenter: Maja Nádorvári
Session: Poster session 08
148P - Clinical significance of CD4+ T cell subsets in peripheral blood for anti-PD-1/PD-L1 therapy
Presenter: Yoshimichi Haruna
Session: Poster session 08
149P - Evaluation of HLA genotype as predictive biomarker for immunological and clinical responses upon vaccination with PolyPEPI1018 cancer vaccine against colorectal cancer
Presenter: Joleen Hubbard
Session: Poster session 08
150P - Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers
Presenter: Albiruni Ryan Abdul Razak
Session: Poster session 08
151P - Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients
Presenter: Ignacio Melero
Session: Poster session 08